Annemarie Laumaea
A5046478751- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- HIV Research and Treatment
- Immune Cell Function and Interaction
- Long-Term Effects of COVID-19
- Animal Virus Infections Studies
- Viral gastroenteritis research and epidemiology
- HIV/AIDS Research and Interventions
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Complement system in diseases
- Mosquito-borne diseases and control
- Platelet Disorders and Treatments
- COVID-19 Impact on Reproduction
- Bacillus and Francisella bacterial research
- Respiratory viral infections research
- Malaria Research and Control
- HIV/AIDS drug development and treatment
- Immunotherapy and Immune Responses
- COVID-19 epidemiological studies
- vaccines and immunoinformatics approaches
- Antimicrobial Peptides and Activities
- Trypanosoma species research and implications
- Heparin-Induced Thrombocytopenia and Thrombosis
Centre Hospitalier de l’Université de Montréal
2020-2023
Université de Montréal
2020-2023
Héma-Québec
2022
Burnet Institute
2013-2021
Bipar
2021
RMIT University
2020
Peter Doherty Institute
2018
The University of Melbourne
2018
Papua New Guinea Institute of Medical Research
2010
HighlightsAntibodies against SARS-CoV-2 Spike correlate with COVID-19 severityRBD-specific IgM and IgA decline more rapidly than IgGSARS-CoV-2 neutralizing antibodies are elicited within 2 weeks of infectionNeutralizing significantly after resolution the infectionSummarySARS-CoV-2 is responsible for coronavirus disease 2019 (COVID-19) pandemic, infecting millions people causing hundreds thousands deaths. The glycoproteins mediate viral entry main targets antibodies. Understanding antibody...
In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, several clinical trials assessing its efficacy are ongoing. While it remains be formally proven, presence neutralizing antibodies thought play a positive role in this treatment. Indeed, titers ≥1:160 have recommended some inclusion. Here, we performed repeated...
With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines, functional and lasting immunity to severe acute respiratory syndrome 2 (SARS-CoV-2) is currently under investigation as antibody levels in plasma were shown decline during convalescence. Since absence antibodies does not equate immune memory, we evaluate presence SARS-CoV-2-specific memory B cells convalescent individuals. Here, report a longitudinal assessment humoral responses on 32 donors up 8...
Characterization of the humoral response to SARS-CoV-2, etiological agent COVID-19, is essential help control infection. The neutralization activity plasma from patients with COVID-19 decreases rapidly during first weeks after recovery. However, specific role each immunoglobulin isotype in overall neutralizing capacity still not well understood. In this study, we select a cohort convalescent and selectively deplete A, M, or G before testing remaining depleted plasma. We find that depletion M...
Where P. vivax and falciparum occur in the same population, peak burden of infection illness is often concentrated younger age groups. Experiences from malaria therapy patients indicate that immunity acquired faster to than challenge. There however little prospective data on comparative risk disease both species young children living co-endemic areas.A cohort 264 Papua New Guinean aged 1-3 years (at enrolment) were actively followed-up for Plasmodium febrile 16 months. Infection status was...
Continuous emergence of SARS-CoV-2 variants concern (VOCs) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number mutations in its Spike raise concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses elicits antibodies efficiently recognize Spikes from different VOCs. Here, we evaluate recognition by plasma cohort naive previously infected...
Abstract The standard dosing of the Pfizer/BioNTech BNT162b2 mRNA vaccine validated in clinical trials includes two doses administered three weeks apart. While decision by some public health authorities to space because limiting supply has raised concerns about efficacy, data indicate that a single dose is up 90% effective starting 14 days after its administration. We analyzed humoral and T cells responses this vaccine. Despite proven efficacy at time point, no neutralizing activity were...
Statistical models of plasma immunovirological features validate SARS-CoV-2 vRNA as an early predictor COVID-19 mortality.
COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that promote SARS-CoV-2 control complex incompletely defined. Using an in vivo imaging approach, we demonstrate CCPs with low (ID50 ≤ 1:250), but moderate to high Fc-effector activity, contrast those poor Fc function, delay mortality and/or improve survival of SARS-CoV-2-challenged K18-hACE2 mice. The impact innate immune cells...
The SARS-CoV-2 virus is responsible for the current worldwide coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds thousands deaths. Spike glycoprotein mediates viral entry main target neutralizing antibodies. Understanding antibody response directed against crucial development vaccine, therapeutic public health interventions. Here we performed a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses Spike. vast...
Abstract Functional and lasting immune responses to the novel coronavirus (SARS-CoV-2) are currently under intense investigation as antibody titers in plasma have been shown decline during convalescence. Since absence of antibodies does not equate memory, we sought determine presence SARS-CoV-2-specific memory B cells COVID-19 convalescent patients. In this study, report on evolution overall humoral 101 blood samples obtained from 32 patients between 16 233 days post-symptom onset. Our...
Dysregulated immune profiles have been described in symptomatic patients infected with SARS-CoV-2. Whether the reported alterations are specific to SARS-CoV-2 infection or also triggered by other acute illnesses remains unclear. We performed flow cytometry analysis on fresh peripheral blood from a consecutive cohort of (a) hospitalized infection, (b) comparable age and sex for another disease (SARS-CoV-2 negative), (c) healthy controls. Using both data-driven hypothesis-driven analyses, we...
Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by Omicron variant concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after second third doses in naive previously infected donors who received their dose with extended 16-week interval. We observe that interval elicits robust against VOCs, but this response is significantly...
Plasmodium falciparum , which causes malaria, extensively remodels its human host cells, particularly erythrocytes. Remodelling is essential for parasite survival by helping to avoid immunity and assisting in the uptake of plasma nutrients fuel rapid growth. Host cell renovation carried out hundreds effector proteins that are exported into erythrocyte across an enveloping parasitophorous vacuole membrane (PVM). The translocon (PTEX) thought span PVM provide a channel unfolds extrudes...
As the coronavirus disease 2019 (COVID-19) pandemic second wave is emerging, it of upmost importance to screen population immunity in order keep track infected individuals. Consequently, immunoassays for severe acute respiratory syndrome 2 (SARS-CoV-2) with high specificity and positive predictive values are needed obtain an accurate epidemiological picture. more data accumulate about immune responses kinetics neutralizing-antibody (nAb) production SARS-CoV-2-infected individuals, new...
Spacing of BNT162b2 mRNA doses beyond 3 weeks raises concerns about vaccine efficacy. We longitudinally analyze B cell, T and humoral responses to two administered 16 apart in 53 SARS-CoV-2 naive previously infected donors. This regimen elicits robust RBD-specific cell whose kinetics differs between cohorts, the second dose leading increased magnitude participants only. While boosting does not increase CD4+ further compared with first dose, unsupervised clustering single-cell features...
Convalescent plasma from SARS-CoV-2 infected individuals and monoclonal antibodies were shown to potently neutralize viral pseudoviral particles carrying the S glycoprotein. However, a non-negligent proportion of samples individuals, as well S-specific antibodies, reported be non-neutralizing despite efficient interaction with glycoprotein in different biochemical assays using soluble recombinant forms or when expressed at cell surface. How neutralization relates binding context remains...
The evaluation of humoral protective immunity against SARS-CoV-2 remains crucial in understanding both natural and conferred by the several vaccines implemented fight COVID-19. reference standard for quantification antibodies capable neutralizing is plaque-reduction neutralization test (PRNT). However, given that it a laboratory-developed assay, validation order to ensure sufficient specificity intra- interassay precision. In addition, multitude other serological assays have been developed,...
ABSTRACT In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across globe for potential transfusion to COVID-19 patients. The therapy has been deemed safe several clinical trials assessing its efficacy are ongoing. While it remains be formally proven, presence neutralizing antibodies thought play a positive role in this treatment. Indeed, titers ≥1:160 have recommended some inclusion. Here we performed repeated analyses at...
The rapid emergence of SARS-CoV-2 variants is fueling the recent waves COVID-19 pandemic. Here, we assessed ACE2 binding and antigenicity Mu (B.1.621) A.2.5 Spikes. Both these carry some mutations shared by other emerging variants. Some pivotal such as N501Y E484K in receptor-binding domain (RBD) detected B.1.1.7 (Alpha), B.1.351 (Beta) P.1 (Gamma) are now present within variant. Similarly, L452R mutation B.1.617.2 (Delta) variant A.2.5. In this study, observed that Spike bound better to...